Nalolax 1mg / 5ml oral solution is indicated for the treatment and maintenance in opioid induced constipation when the response to usual laxative therapy is inadequate. It contains 1mg / 5ml of naloxone in an oral solution. Nalolax is currently in registration in Europe and approval is anticipated in Qtr 4, 2015.
Nalolax has been studied in a series of double blind placebo controlled clinical trials in cancer patients. These patients were receiving a high dose of opioids and exhibited opioid induced constipation (OIC). Nalolax was 40% more efficacious compared to Placebo with p>0.001 and did not compromise pain relief.
We have a range of other products currently in development.